Press Releases

Pivotal trial of BT-001 in type 2 diabetes expected to be fully enrolled in Q4 2021, with primary endpoint readout in Q1 2022; de novo submission to FDA requesting marketing authorization planned following completion of trial  Clinical development of BT-002 and BT-003 in hypertension and

Provides up to $150 million in total financing in combination with proceeds from previously announced SPAC merger and PIPE investment Funds to support advancement of clinical pipeline and commercialization of first prescription digital therapeutic (PDT) for treating type 2 diabetes SAN FRANCISCO--(

Open-label, real-world study will evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at the root cause of type 2 diabetes Study to evaluate the durability of treatment effect and healthcare utilization changes associated with BT-001 in Catalyst’s community-based, clinically

SAN FRANCISCO--( BUSINESS WIRE )-- Better Therapeutics, Inc.  (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the   Canaccord Genuity 41

Open-label, randomized, controlled study will evaluate BT-001’s cognitive behavioral therapy approach to change behaviors at the root cause of type 2 diabetes Study to evaluate the durability of treatment effect and healthcare utilization changes associated with BT-001 in a diverse, real-world

SAN FRANCISCO, June 14, 2021 —  Better Therapeutics, Inc.  (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is scheduled to participate in two virtual panel

  Randomized, controlled, parallel-group study will evaluate the product’s cognitive behavioral therapy approach to changing behaviors that are the root cause of type 2 diabetes Geographically diverse study seeks to enroll 650 people in Texas, Illinois, Florida, California and New York Data on

SAN FRANCISCO, April 20, 2021 — Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Dr. Risa Lavizzo-Mourey to its board of directors; she will also

Transaction values Better Therapeutics at a pro forma fully diluted enterprise value of approximately $187 million with existing Better Therapeutics shareholders rolling over 100% of their equity into equity of the combined company Transaction expected to provide up to $113 million of cash

SAN FRANCISCO-Better Therapeutics, Inc., a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointments of Andrew Armanino and Geoffrey Parker to its board of directors.